LinkZill Secures Tens of Millions in RMB in Pre-A+ Financing to Advance TFT Semiconductor Chips for Life Science Applications

Recently,Hangzhou LinkZill Technology Co., Ltd.(LinkZill, hereinafter referred to as LinkZill)Completed a Pre-A+ financing round of tens of millions of RMB, led by Apricot Capital and followed by ZhenFund。The proceeds from this round of financing will be primarily used to continue advancing the practical application and implementation of TFT semiconductor chips in the life sciences sector.。Yunxiu CapitalServed as the exclusive financial advisor for this round of financing.

LinkZill was established in Wuhan in January 2019, relocated to Hangzhou in January 2020, and founded its Shanghai R&D center in 2021.LinkZill upholds “Leading with Technology, Sincere as One” as its core values, committed to making technology better serve humanity, and adheres to the vision of “Linking zillions of people and technology. Linking zillions of hearts with love.”

LinkZill focuses on thin-film transistor (TFT) semiconductor chips (including supporting drive and test systems and functional materials) as its core products and technologies., and focus on itsIndustrial Applications in Interdisciplinary Fields Such as Life Sciences and Sensing/Display Technologies, currently mainly coveringDigital microfluidics, high-throughput in vitro diagnostic testing, biosensing, high-throughput DNA synthesis, brain-computer interfaces, and frontier research in optoelectronic sensing and display applicationsTo date, LinkZill has served over a hundred global technology enterprises, universities, and research institutes through its core TFT chip technologies, accumulating comprehensive, multi-dimensional technical capabilities and industrialization experience spanning chip design, simulation, fabrication processes, and system integration.

The core team members of LinkZill hail from renowned universities both in China and abroad, including Shanghai Jiao Tong University, the University of Cambridge, the University of Florida, and Huazhong University of Science and Technology. They also possess extensive industry experience gained from leading enterprises such as BOE, TCL CSOT, and Tianma Microelectronics.

LinkZill | Centering on TFT Semiconductor Chips to Drive Industrial Applications in Interdisciplinary Fields Such as Life Sciences and Sensing Displays

The global market size for biochips is currently approaching $20 billion and is experiencing rapid growth, with the potential to reach a hundred-billion-dollar scale in the future. LinkZill’s TFT biochips, developed around typical applications in the life sciences sector, are being gradually adopted by clients and continuing to mature. As the company builds its biological team and establishes its biological laboratories, more new application scenarios are being developed simultaneously.

Dr. Qiang Jing, Managing Partner at Apricot Capital, stated：

Apricot Capital has consistently focused on new platforms and emerging technologies in the frontier life sciences sector, particularly breakthroughs at the intersection of disciplines. Leveraging the strong scalability, flexibility, and cost-effectiveness of thin-film transistor (TFT) technology, LinkZill is actively developing its applications across various scenarios in the life sciences field. In upstream scientific research, interdisciplinary integration has long become a consensus, giving rise to a series of innovative technologies, while downstream there remains a substantial volume of unmet biomedical needs. Therefore, there is an urgent demand for teams that combine forward-thinking vision with foundational technical expertise to deliver novel solutions through technological convergence and engineering implementation. We believe LinkZill is an outstanding team possessing these qualities and is poised to develop a series of products that will bring paradigm-shifting innovations to the life sciences sector.

Yin Le, Partner at ZhenFund, stated：

Since forging a partnership with LinkZill in July 2021, ZhenFund has consistently provided strong support across two consecutive funding rounds. In LinkZill’s endeavors, I see the hallmarks of “disruptive innovation,” and within its team, I witness the remarkable cohesion driven by a strong corporate culture. In this era, LinkZill is destined to experience the full spectrum of entrepreneurial life—the joys and sorrows, the highs and lows—that will accompany its development. I look forward to witnessing this extraordinary journey and LinkZill’s courageous exploration in “surrendering to the flow of life.”

Dr. Yang Yixing, Partner and Chief Marketing Officer at LinkZill, stated：

We are fortunate that our company’s first-ever hands-on involvement in a financing round has ultimately earned the trust and support of Apricot Capital. We extend our gratitude to Apricot Capital, as well as to our partners from ZhenFund and Shiyi Capital, for continuing to believe unwaveringly in our utopian vision for the future of bio-semiconductors, for consistently understanding the steadfast dedication we uphold to realize this dream, and for always embracing the various imperfections we exhibit along our journey. Thank you for your companionship and for walking this path with us.

Dr. Feng Linrun, Founder and CEO of LinkZill, stated：

From the “ten dimensions” of “life’s infinite possibilities,” to ZhenFund’s “we mean business when we start ventures,” and further to Apricot Capital’s “masterful healers, benefiting the world,” it is precisely thanks to the support of these wonderful institutions that LinkZill’s motto, “Leading with Technology, Sincere as Ever,” has gradually transformed from a slogan into reality. Along this journey, there have been countless moments of gratitude and relief, encompassing the full spectrum of life’s joys and sorrows, warmth and coldness. As our team takes shape and the closing of our Pre-A+ financing round is completed, LinkZill will undoubtedly face greater challenges from all fronts. I know I am not yet fully prepared, and perhaps there will never be a day when I feel completely ready. However, looking at the friends and family who have accompanied me along the way, I find the courage to look up at the sky and the determination to keep my feet firmly on the ground. LinkZill, go forth without hesitation in this era that belongs to you, and fulfill your mission with unwavering resolve!

Apricot Capital was established in 2015. Its name, “Apricot,” embodies the ethos of “masterful healers in the apricot grove, bringing benefits to all.” By leveraging the power of capital, Apricot Capital partners with visionary entrepreneurs to address significant unmet clinical needs.

Apricot Capital’s investment team comprises over 20 professionals with extensive experience in healthcare investment, academia, and industry. The firm focuses on innovative biopharmaceuticals, medical devices (including life science instruments), and the innovative services value chain. Its current portfolio includes more than 50 companies, with total assets under management nearing RMB 5 billion.

Since its establishment, Apricot Capital has focused on investing in outstanding early- and growth-stage enterprises in the life sciences industry, with investments spanning biopharmaceuticals, medical devices, and healthcare services. Its portfolio includes over 50 high-growth star companies, such as Junshi Biosciences (01877.HK), Akeso (09926.HK), China Antibody (03681.HK), RemeGen (09995.HK), MicroPort CardioFlow (02160.HK), MicroPort EP MedTech (688351.SH), Sinovant Sciences, Liuhe Ningyuan, InnoMicro, TopAlliance Biosciences, Yilian Biologics, Qihe Life Science, Bowang Pharma, Tianze Yuntai, Shenqi Medical, Shengsheng Logistics, and PharmCube.

ZhenFund is an early-stage investment firm co-founded by Mr. Xu Xiaoping and Mr. Wang Qiang in partnership with Sequoia Capital China in 2011, with total assets under management exceeding RMB 10 billion. Since its inception, ZhenFund has been actively seeking out the most exceptional entrepreneurial teams and epoch-defining investment opportunities in fields such as future technologies, artificial intelligence, enterprise services, healthcare, mass consumer markets, and mobile internet.

ZhenFund has successively invested in more than 800 startups, accompanying companies such as Xiaohongshu (Little Red Book), Nuro, Yitu Technology, Horizon Robotics, Momenta, Enflame Technology, Hesai Technology, XtalPi, AutoX, SmartMore, Aibee, Zhaogang.com, Luoji Siwei (Get), Xingsheng Youxuan, Meicai, and Mobvoi from their early stages to unicorn status. Since 2011, portfolio companies of ZhenFund, including Jiayuan.com (NASDAQ: DATE), Jumei International Holding Ltd. (NYSE: JMEI), LightInTheBox (NYSE: LITB), 51Talk (NYSE: COE), NIU Technologies (NASDAQ: NIU), Tiger Brokers (NASDAQ: TIGR), EHang Holdings Limited (NASDAQ: EH), Yatsen Holding Limited (NYSE: YSG), Ucommune International Ltd (NASDAQ: UK), Shuidao Inc. (NYSE: WDH), and DeepGlint (688207), have gone public one after another.